These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15754530)

  • 41. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
    Raez LE; Kobina S; Santos ES
    Clin Lung Cancer; 2010 Jan; 11(1):18-24. PubMed ID: 20085863
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.
    Pendyala L; Creaven PJ
    Cancer Res; 1993 Dec; 53(24):5970-6. PubMed ID: 8261411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer.
    Becouarn Y; Rougier P
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):23-31. PubMed ID: 9609105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Platinum compounds in cancer therapy--past, present, and future].
    Akaza H; Saijo N; Aiba K; Isonishi S; Ohashi Y; Kawai K; Konishi T; Saeki T; Sone S; Tsukagoshi S; Tsuruo T; Noguchi S; Miki T; Mikami O; Smith M; Hoctin-Boes G; Stribling D
    Gan To Kagaku Ryoho; 2001 May; 28(5):625-35. PubMed ID: 11383210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of the platinum analogues in bladder cancer cell lines.
    Powles T; Perry J; Shamash J; Liu W; Oliver T; Joel S
    Urol Int; 2007; 79(1):67-72. PubMed ID: 17627172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
    Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
    Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
    Luo FR; Wyrick SD; Chaney SG
    Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results.
    Merkel U; Wedding U; Roskos M; Höffken K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):475-9. PubMed ID: 12877360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients.
    Ishibashi T; Yano Y; Oguma T
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):230-6. PubMed ID: 12203105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.
    Mathé G; Kidani Y; Segiguchi M; Eriguchi M; Fredj G; Peytavin G; Misset JL; Brienza S; de Vassals F; Chenu E
    Biomed Pharmacother; 1989; 43(4):237-50. PubMed ID: 2675999
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The current status of new platinum analogs.
    Christian MC
    Semin Oncol; 1992 Dec; 19(6):720-33. PubMed ID: 1462169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates.
    McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
    Cancer Chemother Pharmacol; 1994; 33(6):497-503. PubMed ID: 8137461
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical pharmacokinetics and administration of established platinum drugs.
    O'Dwyer PJ; Stevenson JP; Johnson SW
    Drugs; 2000; 59 Suppl 4():19-27. PubMed ID: 10864227
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carboplatin: a clinical review.
    Yarbro CH
    Semin Oncol Nurs; 1989 May; 5(2 Suppl 1):63-9. PubMed ID: 2657932
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Status of bi- and multi-nuclear platinum anticancer drug development.
    Zhang J; Wang L; Xing Z; Liu D; Sun J; Li X; Zhang Y
    Anticancer Agents Med Chem; 2010 May; 10(4):272-82. PubMed ID: 20184553
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cellular and molecular pharmacology of oxaliplatin.
    Raymond E; Faivre S; Chaney S; Woynarowski J; Cvitkovic E
    Mol Cancer Ther; 2002 Jan; 1(3):227-35. PubMed ID: 12467217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nanocarriers for delivery of platinum anticancer drugs.
    Oberoi HS; Nukolova NV; Kabanov AV; Bronich TK
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1667-85. PubMed ID: 24113520
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation.
    Kawai Y; Taniuchi S; Okahara S; Nakamura M; Gemba M
    Biol Pharm Bull; 2005 Aug; 28(8):1385-8. PubMed ID: 16079479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.